---
title: "__NewInstitute__ Quality Manual"
subtitle: "SOP-009: Monitoring and Oversight Procedure"
---

## 1.0 PURPOSE

This Standard Operating Procedure (SOP) establishes the systematic approach for
monitoring and oversight of *observational studies* conducted by
__NewInstitute__. It ensures that studies are conducted in accordance with the
protocol, GCP, and regulatory requirements while maintaining data quality and
subject safety.

## 2.0 SCOPE

This procedure applies to the execution and documentation of all monitoring
and oversight activities for *observational studies* conducted by
__NewInstitute__. It implements the risk-based monitoring approach defined in
the study's Risk Management Plan to ensure studies are conducted in accordance
with the protocol, GCP, and applicable regulatory requirements while
maintaining data quality and subject safety.

This procedure applies to monitoring of:

- **External clinical sites**: Sites and investigators qualified per [SOP-006:
  Outsourced Activities Procedure](SOP-006--Outsourced_Activities_Procedure.md)
  that perform study-related activities including subject enrollment, data
  collection, and study procedures

- **Internal data collection activities**: Data collection conducted directly
  by __NewInstitute__ or through direct-to-subject mechanisms, including
  wearable devices, mobile applications, electronic patient-reported outcomes,
  and other digital health technologies

The monitoring approach for each study is determined based on the Risk
Management Plan developed under [SOP-003: Risk Management and Quality Risk
Management Procedure](SOP-003--Risk_Management_and_Quality_Risk_Management_Procedure.md).
The Monitoring Plan operationalizes the risk-based approach by translating
identified risks and critical to quality factors into specific monitoring
activities proportionate to study complexity and risk.

Study protocols being monitored are developed under [SOP-001: Design Controls
Procedure](SOP-001--Design_Controls_Procedure.md).

Monitoring reports and documentation are controlled under [SOP-002: Document
and Records Controls
Procedure](SOP-002--Document_and_Records_Controls_Procedure.md) and maintained
in the TMF.

Monitoring findings that identify nonconformances are managed under [SOP-010:
Control of Nonconforming Observational Study Activities
Procedure](SOP-010--Control_of_Nonconforming_Observational_Study_Activities_Procedure.md).

Issues requiring corrective action are managed under [SOP-011: Corrective and
Preventive Action
Procedure](SOP-011--Corrective_and_Preventive_Action_Procedure.md).

This procedure applies to all __NewInstitute__ employees and subcontractors
involved in monitoring and oversight activities.

## 3.0 REFERENCES, TERMS AND ACRONYMS

### 3.1 Guidance and Regulatory References

- [ICH E6(R2)](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e6r2-good-clinical-practice-integrated-addendum-ich-e6r1):
  Good Clinical Practice: Integrated Addendum to ICH E6(R1)
  - Section 5.18 (monitoring)
  - Section 5.20 (noncompliance)
  - Addendum Section 5.0 (quality management)

- [ICH E8(R1)](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e8r1-general-considerations-clinical-studies):
  General Considerations for Clinical Studies
  - Section 6 (conduct, safety monitoring, and reporting)a

- [FDA Guidance: Oversight of Clinical Investigations â€” A Risk-Based Approach to Monitoring (August 2013)](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/oversight-clinical-investigations-risk-based-approach-monitoring)

- [FDA Guidance: A Risk-Based Approach to Monitoring of Clinical Investigations: Questions and Answers (2023)](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/risk-based-approach-monitoring-clinical-investigations-questions-and-answers)

### 3.2 __NewInstitute__ References

1. [QM-001: Quality Manual](QM-001--QualityManual.md)

2. [SOP-001: Design Controls Procedure](SOP-001--Design_Controls_Procedure.md)

3. [SOP-002: Document and Records Controls
   Procedure](SOP-002--Document_and_Records_Controls_Procedure.md)

4. [SOP-003: Risk Management and Quality Risk Management
   Procedure](SOP-003--Risk_Management_and_Quality_Risk_Management_Procedure.md)

5. [SOP-006: Outsourced Activities
   Procedure](SOP-006--Outsourced_Activities_Procedure.md)

6. [SOP-010: Control of Nonconforming Observational Study Activities
   Procedure](SOP-010--Control_of_Nonconforming_Observational_Study_Activities_Procedure.md)

7. [SOP-011: Corrective and Preventive Action
   Procedure](SOP-011--Corrective_and_Preventive_Action_Procedure.md)

### 3.3 Terms

- **Centralized Monitoring**: Remote evaluation of accumulating data performed in
  a timely manner by appropriately qualified and trained persons at a location
  other than the sites at which the study is being conducted. Centralized
  monitoring processes may include statistical analyses to identify data trends,
  site performance issues, or data anomalies.

- **Critical Data**: Data that if inaccurate, incomplete, or missing would
  threaten the protection of human subjects or the integrity of study results.
  Examples include data related to informed consent, eligibility criteria, study
  endpoints, and safety assessments.

- **Critical Process**: A process that if not performed or performed incorrectly
  would threaten the protection of human subjects or the integrity of study
  results.

- **For-Cause Visit**: An unscheduled on-site monitoring visit triggered by
  specific concerns identified through centralized monitoring, performance
  metrics, or other sources.

- **Key Risk Indicator (KRI)**: A metric used to monitor identified risks and
  detect when risk levels exceed acceptable thresholds.

- **Monitoring**: The act of overseeing the progress of a study and ensuring that
  it is conducted, recorded, and reported in accordance with the protocol, SOPs,
  GCP, and applicable regulatory requirements. [ICH E6(R2) 1.38]

- **Monitoring Plan**: A document that describes the monitoring strategy, methods,
  responsibilities, and requirements for a specific study, including the
  rationale for the monitoring approach.

- **On-Site Monitoring**: In-person evaluation carried out by sponsor personnel or
  representatives at the sites at which the study is being conducted.

- **Quality Tolerance Limit (QTL)**: A predefined threshold for a quality
  parameter that, if exceeded, triggers evaluation and potential corrective
  action. QTLs are established during study design per SOP-003.

- **Remote Monitoring**: Monitoring activities conducted without physical presence
  at the study site, such as telephone or video communication with site personnel
  and remote review of documents.

- **Site Initiation Visit (SIV)**: A visit conducted before enrollment begins at a
  site to confirm site readiness, provide study-specific training, and verify
  that all prerequisites for study conduct are in place.

- **Source Data**: All information in original records and certified copies of
  original records of clinical findings, observations, or other activities in a
  study necessary for the reconstruction and evaluation of the study.
  [ICH E6(R2) 1.51]

- **Source Data Verification (SDV)**: The process of comparing data entered in the
  case report form or electronic data capture system against source documents to
  confirm accuracy and completeness.

- **Source Document**: Original documents, data, and records where source data are
  first recorded. [ICH E6(R2) 1.52]

### 3.4 Acronyms

- **CRA**: Clinical Research Associate
- **EDC**: Electronic Data Capture
- **GCP**: Good Clinical Practice
- **KRI**: Key Risk Indicator
- **QTL**: Quality Tolerance Limit
- **RMP**: Risk Management Plan
- **SDV**: Source Data Verification
- **SIV**: Site Initiation Visit
- **TMF**: Trial Master File

## 4.0 PROCEDURE

### 4.1 Overview

This procedure establishes requirements for:

- Developing a Monitoring Plan for each study based on the Risk Management Plan
- Conducting site initiation activities before enrollment begins
- Executing ongoing monitoring through centralized and on-site methods
- Managing and escalating issues identified through monitoring
- Adapting monitoring approach based on emerging data and findings
- Conducting close-out monitoring activities
- Documenting and reporting monitoring activities

The purpose of monitoring is to verify that:

- The rights and well-being of study subjects are protected
- Reported study data are accurate, complete, and verifiable from source
  documents
- The study is conducted in compliance with the approved protocol, GCP, and
  applicable regulatory requirements

Monitoring activities **SHALL** be proportionate to study risks as identified in
the Risk Management Plan per SOP-003. Studies with higher complexity, novel
procedures, or greater risks to subject safety or data integrity may require
more intensive monitoring. Studies with lower risk profiles may rely primarily
on centralized monitoring with limited on-site activities.

### 4.2 Monitoring Plan Development

#### 4.2.1 Monitoring Plan Requirements

A Monitoring Plan **SHALL** be developed for each study before study initiation.
The Monitoring Plan operationalizes the risk-based monitoring approach by
translating the Risk Management Plan into specific monitoring activities.

The Monitoring Plan **SHALL** be informed by:

- The Risk Management Plan developed per SOP-003, including identified critical
  data and processes, risk assessments, and Quality Tolerance Limits (QTLs)
- Study design complexity and objectives
- Types of data being collected and data sources (external sites, direct-to-
  subject, wearables, etc.)
- Study population characteristics
- Geographic distribution of sites
- Experience level of investigators and site staff

#### 4.2.2 Monitoring Plan Content

The Monitoring Plan **SHALL** include:

- **Monitoring strategy and rationale**: Description of the overall monitoring
  approach (centralized, on-site, or combination) with justification based on
  study-specific risks

- **Critical data and processes**: Identification of data and processes
  requiring monitoring focus, derived from the Risk Management Plan

- **Monitoring methods**: Description of each monitoring method to be used,
  including:
  - Centralized monitoring activities (data review, statistical analyses, KRI
    tracking)
  - On-site monitoring activities, if planned
  - Remote monitoring activities (document review, site communication)
  - Source data verification approach and extent

- **Monitoring frequency and timing**: Criteria for determining when monitoring
  activities will occur, including:
  - Frequency of centralized data reviews
  - Triggers for on-site visits (routine or for-cause)
  - Timing relative to enrollment milestones

- **Key Risk Indicators (KRIs)**: Metrics to be tracked with thresholds that
  trigger evaluation or action, aligned with QTLs from the Risk Management Plan

- **Roles and responsibilities**: Identification of personnel responsible for
  monitoring activities

- **Communication and reporting**: Processes for reporting monitoring results
  to study management and for communicating findings to sites

- **Issue escalation**: Criteria and process for escalating significant findings
  per SOP-010 and SOP-011

- **Monitoring tools**: Checklists, report templates, and other tools to be used

#### 4.2.3 Monitoring Plan Review and Approval

The Monitoring Plan **SHALL** be reviewed and approved before study initiation.
The review **SHALL** confirm that:

- The monitoring approach is proportionate to identified risks
- Critical data and processes are adequately addressed
- Monitoring methods are appropriate for the study design and data sources
- Resources are adequate to execute the plan

The approved Monitoring Plan **SHALL** be maintained in the TMF.

### 4.3 Site Initiation and Activation

#### 4.3.1 Site Initiation Requirements

Before a site begins enrollment, __NewInstitute__ **SHALL** confirm site
readiness through site initiation activities. Site initiation may be conducted
through on-site visits, remote methods, or a combination, as specified in the
Monitoring Plan.

Site initiation activities **SHALL** verify:

- IRB/IEC approval is in place for the protocol and informed consent
- Investigator and site staff qualifications are documented per SOP-006
- Required training has been completed and documented
- Study supplies and materials are available
- Data collection systems are accessible and functional
- Source document templates and procedures are established
- Site facilities and equipment are adequate for study conduct
- Financial disclosure documentation is complete per 21 CFR Part 54
- Signed investigator agreements are in place

#### 4.3.2 Site Initiation Documentation

Site initiation activities **SHALL** be documented, including:

- Date and method of initiation (on-site visit, remote, or hybrid)
- Personnel participating in initiation activities
- Verification that readiness criteria were met
- Any issues identified and resolution status
- Authorization to begin enrollment

Site initiation documentation **SHALL** be maintained in the TMF.

#### 4.3.3 Internal Data Collection Initiation

For studies involving internal data collection (wearables, mobile applications,
direct-to-subject data collection), initiation activities **SHALL** verify:

- Data collection systems are validated per SOP-004
- Data flow from collection point to study database is confirmed
- Subject-facing instructions and support processes are in place
- Data quality checks and monitoring dashboards are operational

### 4.4 Ongoing Monitoring

#### 4.4.1 Centralized Monitoring

Centralized monitoring **SHALL** be the primary method for ongoing study
oversight. Centralized monitoring activities **SHALL** include, as appropriate
to the study:

- **Routine data review**: Review of submitted data to identify missing data,
  inconsistencies, data outliers, protocol deviations, and data entry errors

- **Statistical monitoring**: Analyses to identify data trends, unusual
  distributions, or anomalies across sites, including:
  - Checks for range, consistency, and completeness
  - Comparison of data patterns within and between sites
  - Identification of sites with atypical data distributions

- **KRI tracking**: Monitoring of Key Risk Indicators against established
  thresholds, including:
  - Enrollment metrics (screen failure rates, enrollment rates)
  - Data quality metrics (query rates, missing data rates, error rates)
  - Protocol compliance metrics (deviation rates, visit compliance)
  - Safety metrics (adverse event reporting patterns)

- **QTL monitoring**: Tracking of Quality Tolerance Limits established in the
  Risk Management Plan, with evaluation when thresholds are exceeded

- **Remote document review**: Review of essential documents submitted
  electronically, including regulatory documents, consent forms, and training
  records

The frequency of centralized monitoring activities **SHALL** be specified in the
Monitoring Plan and **SHALL** be sufficient to identify issues in a timely
manner.

#### 4.4.2 On-Site Monitoring

On-site monitoring visits **MAY** be conducted based on the Monitoring Plan
and as triggered by centralized monitoring findings. On-site monitoring is not
required for all studies but **SHALL** be considered when:

- Study complexity or risk profile warrants direct observation
- Centralized monitoring identifies concerns requiring in-person assessment
- Site performance metrics indicate potential issues
- Protocol procedures require on-site verification
- Regulatory requirements specify on-site monitoring

When conducted, on-site monitoring visits **SHALL** address:

- Source data verification for critical data elements as specified in the
  Monitoring Plan
- Review of informed consent process and documentation
- Verification of protocol compliance
- Assessment of site facilities, equipment, and processes
- Review of investigational product accountability, if applicable
- Discussion of findings and corrective actions with site staff
- Training or re-training as needed

#### 4.4.3 For-Cause Visits

For-cause visits **SHALL** be conducted when centralized monitoring or other
sources identify significant concerns requiring immediate on-site assessment.
Triggers for for-cause visits include:

- KRI or QTL thresholds exceeded without adequate explanation
- Patterns suggesting potential data integrity issues
- Significant or repeated protocol deviations
- Safety concerns or unreported adverse events
- Complaints or reports regarding site conduct
- Significant enrollment or data quality anomalies

For-cause visits **SHALL** be documented with clear description of the trigger,
findings, and required corrective actions.

#### 4.4.4 Source Data Verification

The extent and approach to source data verification (SDV) **SHALL** be defined
in the Monitoring Plan based on risk assessment. SDV **SHALL** focus on:

- Critical data elements identified in the Risk Management Plan
- Data directly supporting study endpoints
- Safety data and adverse event documentation
- Informed consent documentation
- Eligibility verification

The Monitoring Plan **SHALL** specify the percentage and selection method for
SDV (e.g., 100% for critical endpoints, risk-based sampling for other data).
SDV may be conducted on-site or remotely where electronic source documents are
accessible.

#### 4.4.5 Communication with Sites

Regular communication with sites **SHALL** be maintained throughout the study.
Communication activities include:

- Sharing centralized monitoring findings and trends
- Providing feedback on site performance
- Clarifying protocol requirements
- Addressing site questions and concerns
- Communicating study-wide updates and lessons learned

Communication **MAY** be conducted through site calls, newsletters, email, or
other methods specified in the Monitoring Plan.

### 4.5 Issue Management and Escalation

#### 4.5.1 Issue Identification and Documentation

Issues identified through monitoring activities **SHALL** be documented,
including:

- Description of the issue
- Date identified and method of identification
- Affected site(s) or data
- Severity assessment
- Required corrective actions
- Responsible party and due date for resolution

#### 4.5.2 Issue Classification

Issues **SHALL** be classified by severity to guide response:

- **Critical**: Issues that may affect subject safety, compromise data integrity
  for primary endpoints, or indicate potential serious noncompliance. Critical
  issues require immediate escalation and corrective action.

- **Major**: Issues that may affect data quality or indicate protocol
  noncompliance but do not immediately threaten subject safety or primary
  endpoint integrity. Major issues require prompt corrective action.

- **Minor**: Issues that represent isolated errors or minor deviations with
  limited impact on data quality or study conduct. Minor issues require
  correction but may be addressed through routine processes.

#### 4.5.3 Escalation

Critical and major issues **SHALL** be escalated per the following:

- **Critical issues**: Immediate notification to study management and, as
  appropriate, to the IRB/IEC, regulatory authorities, or sponsor. Critical
  issues **SHALL** be managed as nonconformances per SOP-010.

- **Major issues**: Notification to study management within timeframes specified
  in the Monitoring Plan. Repeated or systemic major issues **SHALL** be
  referred for CAPA evaluation per SOP-011.

- **Trends and patterns**: Identification of trends across sites **SHALL** be
  reported to study management for evaluation of systemic issues and potential
  CAPA per SOP-011.

### 4.6 Monitoring Adaptations

#### 4.6.1 Adaptive Monitoring

The monitoring approach **SHALL** be adapted during study conduct based on:

- Emerging data and centralized monitoring findings
- Changes in study risk profile
- Site performance trends
- Resource availability
- Protocol amendments affecting monitoring requirements

#### 4.6.2 Triggers for Monitoring Changes

Monitoring intensity or methods **MAY** be adjusted when:

- Sites demonstrate consistent high performance (reduced monitoring)
- Sites demonstrate performance concerns (increased monitoring)
- KRI or QTL thresholds are exceeded
- New risks are identified
- Study complexity changes due to protocol amendments

#### 4.6.3 Documentation of Adaptations

Changes to the monitoring approach **SHALL** be documented, including:

- Rationale for the change
- Specific modifications to monitoring activities
- Effective date
- Approval by appropriate personnel

Significant changes **SHALL** be documented as Monitoring Plan amendments and
maintained in the TMF.

### 4.7 Close-Out Monitoring

#### 4.7.1 Close-Out Requirements

Close-out monitoring activities **SHALL** be conducted for each site upon
completion of study activities. Close-out may be conducted through on-site
visits or remote methods, as appropriate.

Close-out activities **SHALL** verify:

- All data have been collected, queried, and resolved
- All adverse events have been followed to resolution or stability
- Informed consent documentation is complete for all subjects
- Source documents are complete and will be retained per requirements
- Essential documents are complete and filed appropriately
- Outstanding issues have been resolved or documented
- Site is aware of record retention requirements

#### 4.7.2 Close-Out Documentation

Close-out activities **SHALL** be documented, including:

- Date and method of close-out
- Confirmation that close-out requirements were met
- Any outstanding issues and plan for resolution
- Record retention acknowledgment from site

Close-out documentation **SHALL** be maintained in the TMF.

### 4.8 Monitoring Reports and Documentation

#### 4.8.1 Monitoring Visit Reports

Each monitoring visit (on-site, remote, or site initiation/close-out) **SHALL**
be documented in a monitoring report. Reports **SHALL** include:

- Date of activity and site/location
- Personnel conducting the activity
- Summary of activities performed
- Findings, including any noncompliance, data irregularities, or deficiencies
- Actions taken, to be taken, or recommended
- Responsible party and due dates for follow-up actions
- Confirmation that previous action items were addressed

Monitoring reports **SHALL** be completed in a timely manner and maintained in
the TMF.

#### 4.8.2 Centralized Monitoring Reports

Centralized monitoring activities **SHALL** be documented at intervals specified
in the Monitoring Plan. Reports **SHALL** include:

- Period covered
- Data and metrics reviewed
- KRI and QTL status
- Trends and patterns identified
- Sites or issues flagged for follow-up
- Recommendations for monitoring adaptations

#### 4.8.3 Management Oversight Reports

Summary reports **SHALL** be provided to study management at intervals specified
in the Monitoring Plan. Reports **SHALL** include:

- Overall monitoring status and activities completed
- Summary of findings by category and severity
- KRI and QTL dashboard
- Site performance summary
- Outstanding issues and escalations
- Recommendations for study-level actions

#### 4.8.4 Documentation Retention

All monitoring documentation **SHALL** be maintained in the TMF per SOP-002 and
retained per applicable regulatory requirements.

## 5.0 TRAINING

Personnel involved in monitoring activities **SHALL** be trained before
performing monitoring functions. Training **SHALL** be commensurate with the
individual's role and responsibilities.

Training **SHALL** include:

- **General training**: Principles of GCP, human subjects protection, and
  regulatory requirements applicable to monitoring

- **Procedure training**: This SOP and related procedures (SOP-003, SOP-010,
  SOP-011)

- **Study-specific training**: Protocol requirements, Monitoring Plan,
  study-specific procedures, critical data and processes, data collection
  systems, and monitoring tools for each study

Personnel conducting on-site monitoring or source data verification **SHALL**
have training and experience appropriate to the complexity of the study and
monitoring activities.

Training **SHALL** be documented and records maintained per SOP-002. Training
records for study-specific monitoring activities **SHALL** be maintained in the
TMF.

Retraining **SHALL** be conducted when:

- Significant changes are made to this procedure
- Protocol amendments affect monitoring requirements
- Monitoring Plan amendments change monitoring activities
- Performance issues indicate a need for additional training

## 6.0 RECORDS

The following records **SHALL** be generated and maintained per this procedure:

- **Monitoring Plan**: Approved monitoring plan for each study, including any
  amendments

- **Site initiation documentation**: Records of site initiation activities,
  readiness verification, and authorization to enroll

- **Monitoring visit reports**: Documentation of each on-site, remote, and
  for-cause monitoring visit

- **Centralized monitoring reports**: Periodic reports documenting centralized
  monitoring activities, findings, and trends

- **Management oversight reports**: Summary reports provided to study management

- **Issue logs**: Documentation of issues identified, classification, corrective
  actions, and resolution status

- **KRI and QTL tracking records**: Documentation of Key Risk Indicator and
  Quality Tolerance Limit monitoring

- **Source data verification records**: Documentation of SDV activities
  performed and findings

- **Site close-out documentation**: Records of close-out activities and
  confirmation of completion

- **Training records**: Documentation of training completed by monitoring
  personnel for study-specific activities

All monitoring records **SHALL** be maintained in the TMF per SOP-002.

Records **SHALL** be retained per the retention periods specified in the
protocol and applicable regulatory requirements, but not less than the period
required by ICH E6(R2) Section 4.9.5 (investigator records) and Section 5.5.12
(sponsor records).
